Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Oct 8;17:17562864241277736. doi: 10.1177/17562864241277736

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2024

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 7. — Multivariate model for risk of infections and SIs in (a) OPERA and (b) ORATORIO. (a) Risk of all infections and SIs in OPERA (RMS) over a period of up to 11.2 years. (b) Risk of all infections and SIs in ORATORIO (PPMS), over a period of up to 11.8 years. Significant covariates (p-values < 0.05) are marked in bold.

Covariates were selected from univariate models if their significance level was p ⩽ 0.2. Each model (RMS/PPMS and all infections/SIs) was treated independently, which may result in different covariates being selected. For example, IgG < LLN was not selected for the multivariate analysis of all infections, but it was selected for the multivariate analysis of SIs in patients with RMS in OPERA. Covariates with no results (marked “-”) correspond to covariates not selected from the univariate analysis due to its significance level being p > 0.2. CCOD, November 2022.

BMI, body mass index; CCOD, clinical cut-off date; CI, confidence interval; DMT, disease-modifying therapy; EDSS, Expanded Disability Status Scale; Ig, immunoglobulin; LLN, lower limit of normal; OCR, ocrelizumab; PPMS, primary progressive multiple sclerosis; RMS, relapsing multiple sclerosis; ROW, rest of the world; RR, rate ratio; SI, serious infection.